Tenax Therapeutics, Inc. downgraded to Hold ahead of Aug 2026 phase 3 TNX-103 data in PH-HFpEF; weigh 6MWD odds, downside, ...
Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation ...
The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting ...
As humans, our eyes take in two-dimensional images that our brains convert to three-dimensional experiences. This ability enables us to be aware of our position in space, judge distances, possess ...
The company rolled out a biology-centric version of Claude and hosted surprisingly forthright conversations about AI and ...
Building a clean, professional presentation deck from scratch is one of the most reliable ways to eat up an afternoon. Even ...
Anthropic's Claude Science is a workbench that gives scientists one environment to do computational research, saving them ...
An innovative partnership has yielded powerful new tools to help federal agencies rapidly synthesize complex data, historical ...
The teams that get full value from reality capture treat human change as the real implementation. They build the new workflow ...
VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced ...
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline ...
Driving” (FSD) system, Tesla has presented self-published safety statistics to regulators in Sweden and the Netherlands that independent traffic-safety researchers have said amount to misleading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results